

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number
WO 2003/059953 A3

(51) International Patent Classification⁷: **C07K 16/42**,
C12N 5/20, A61K 39/395, A61P 31/18

(21) International Application Number:
PCT/EP2003/000455

(22) International Filing Date: 17 January 2003 (17.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02 001 250.6 17 January 2002 (17.01.2002) EP

(71) Applicant (for all designated States except US):
**POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE
FORSCHUNG GMBH** [AT/AT]; Nussdorfer Lände 11,
A-1190 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KUNERT, Renate**

[AT/AT]; Galileigasse 5, A-2232 Deutsch-Wagram (AT).
WEIK, Robert [AT/AT]; Hohlweggasse 2/10, A-1030 Vi-
enna (AT). **STIEGLER, Gabriela** [AT/AT]; Bahnstrasse
56, A-3481 Fels am Wagram (AT). **KATINGER, Her-
mann** [AT/AT]; Heiligenstädterstrasse 127A/7/8, A-1190
Vienna (AT).


(74) Agent: **BÜCHEL, KAMINSKI & PARTNER**; Austrasse
79, FL-9490 Vaduz (LI).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI,

[Continued on next page]

(54) Title: ANTI-IDIOTYPIC ANTIBODY INDUCING HIV-1 NEUTRALIZING ANTIBODIES



(57) Abstract: The invention relates to Ab2-type anti-idiotypic antibodies and fragments thereof which mimic HIV-1 epitopes that are otherwise cryptic to the immune system and which antibodies or fragments thereof are directed against potentially neutralizing anti-HIV-1 antibodies. The invention further relates to a hybridoma cell line 3H6 expressing the anti-idiotypic antibody and to pharmaceutical compositions containing said antibody or fragment thereof. The invention also relates to HIV-1 neutralizing Ab3-type antibodies elicited upon administration of a said Ab2-type anti-idiotypic antibody or fragment thereof and to pharmaceutical compositions containing them. The invention also relates to the use of the present antibodies or fragments thereof as screening tools or as diagnostic or therapeutic agents.



SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Date of publication of the amended claims: 26 February 2004

Published:

- with international search report
- with amended claims

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:
18 December 2003

International Publication No
PCT/EP 03/00455

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K16/42 C12N5/20 A61K39/395 A61P31/18

B. FIELDS SEARCHED

IPC 7 C07K

BIOSIS, EMBASE, CHEM ABS Data, WPI Data, PAJ, EPO-Internal, SEQUENCE SEARCH

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

Y

1-4, 9,
15-17

Y

7,8,
10-14,18

Y M. FUNG ET AL.: "Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 gp120 induces HIV-1 neutralizing antibodies in rabbits." THE JOURNAL OF IMMUNOLOGY, vol. 145, no. 7, 1 October 1990 (1990-10-01), pages 2199-2206, XP002125226 Baltimore, MD, USA abstract

5, 6,
10-13, 18

— / —

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

*& document member of the same patent family

Date of the actual completion of the international search

16 July 2003

Date of mailing of the international search report

24/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer _____

Nooij, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/00455

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 503 916 A (IDEC PHARMACEUTICALS CORPORATION) 16 September 1992 (1992-09-16) examples claims	5,6, 10-13,18
Y	EP 0 498 767 A (CIBA-GEIGY AG) 12 August 1992 (1992-08-12) examples claims	7
Y	WO 97 34636 A (IMMUNOMEDICS INC.) 25 September 1997 (1997-09-25) examples claims	7
Y	WO 94 08601 A (THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY) 28 April 1994 (1994-04-28) examples claims	8
Y	S. HINUMA ET AL.: "A novel strategy for converting recombinant viral protein into high immunogenic protein." FEBS LETTERS, vol. 288, no. 1-2, August 1991 (1991-08), pages 138-142, XP002016293 Amsterdam, The Netherlands abstract	8
Y	WO 98 17799 A (THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA & APOLLON, INC.) 30 April 1998 (1998-04-30) claims 1-8	8
Y	WO 97 16204 A (SCHERING CORPORATION) 9 May 1997 (1997-05-09) page 4, line 5 - line 16 claims 1,16,18	14
Y	C. POHL ET AL.: "CD30-specific Ab1-Ab2-Ab3 internal image antibody network: Potential use as anti-idiotypic vaccine against Hodgkin's lymphoma." INTERNATIONAL JOURNAL OF CANCER, vol. 54, 28 May 1993 (1993-05-28), pages 418-425, XP000647479 New York, NY, USA abstract page 422, right-hand column, line 7 - line 50	18

	-/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/00455

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>H. KÖHLER & C. MILSTEIN: "Continuous cultures of fused cells secreting antibody of predefined specificity." NATURE, vol. 256, 7 August 1975 (1975-08-07), pages 495-497, XP000650513 London, GB the whole document</p>	<p>5,6,10, 11</p>

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/00455

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 570357	A	18-11-1993	AT 403050 B	27-10-1997
			AT 98792 A	15-03-1997
			CA 2096159 A1	15-11-1993
			DE 69311764 D1	31-07-1997
			DE 69311764 T2	05-02-1998
			DE 570357 T1	28-07-1994
			EP 0570357 A2	18-11-1993
			ES 2053413 T1	01-08-1994
			JP 3369246 B2	20-01-2003
			JP 6293797 A	21-10-1994
			US 5693752 A	02-12-1997
			US 5866694 A	02-02-1999
EP 503916	A	16-09-1992	AU 1538392 A	06-10-1992
			EP 0503916 A1	16-09-1992
			IE 920785 A1	23-09-1992
			WO 9215885 A1	17-09-1992
			ZA 9201799 A	25-11-1992
EP 498767	A	12-08-1992	AU 1025692 A	13-08-1992
			CA 2060626 A1	07-08-1992
			EP 0498767 A2	12-08-1992
			IE 920386 A1	12-08-1992
			JP 5292994 A	09-11-1993
WO 9734636	A	25-09-1997	AU 2342897 A	10-10-1997
			CA 2250080 A1	25-09-1997
			EP 0939653 A1	08-09-1999
			JP 2000511403 T	05-09-2000
			WO 9734636 A1	25-09-1997
WO 9408601	A	28-04-1994	AU 5361794 A	09-05-1994
			WO 9408601 A1	28-04-1994
			US 6099846 A	08-08-2000
WO 9817799	A	30-04-1998	AU 729579 B2	01-02-2001
			AU 5002297 A	15-05-1998
			BR 9712852 A	16-11-1999
			EP 0958364 A1	24-11-1999
			JP 2001507216 T	05-06-2001
			KR 2000052710 A	25-08-2000
			WO 9817799 A1	30-04-1998
WO 9716204	A	09-05-1997	AU 7473096 A	22-05-1997
			CA 2236591 A1	09-05-1997
			CA 2329474 A1	09-05-1997
			EP 0858343 A1	19-08-1998
			JP 2000507917 T	27-06-2000
			WO 9716204 A1	09-05-1997
			US 6461605 B1	08-10-2002
			US 6177074 B1	23-01-2001
			US 6524570 B1	25-02-2003
			US 5908621 A	01-06-1999